Dortmund, Germany, March 24, 2026 – iDEL Therapeutics today announced the appointment of accomplished biopharmaceutical executive Claudia Ulbrich, MD, as the Chair of its Board of Directors. Dr. Ulbrich brings[…]

Dortmund, Germany, March 17, 2026 – iDEL Therapeutics today announced the closing of a EUR 9 million seed financing, establishing its operations and leadership team. The company is pioneering a[…]